盐酸依立替康与米托蒽醌等联合治疗非霍奇金淋巴瘤不良反应的观察与护理

Adverse reactions of patients with non-hodgkin′s lymphoma to combined treatment with irinotecan HCI and mitoxantrone

目的探讨难治、复发性非霍奇金淋巴瘤经盐酸依立替康与米托蒽醌等联合治疗的不良反应与护理对策。方法对12例非霍奇金淋巴瘤患者经盐酸依立替康与米托蒽醌等联合治疗后引起的迟发性腹泻、中性粒细胞减少、恶心、呕吐、便秘等不良反应逐一观察发生时间、次数、症状并给予相应护理。结果 4例患者完全缓解,4例患者部分缓解,总有效率66.6%。经过细致周全的护理12例患者不良反应均得到有效控制,无其他并发症发生。结论严密观察化疗不良反应,采取积极有效的护理措施,可减轻患者痛苦,提高疗效。

Objective To study the adverse reactions of patients with refractory and relapsing non-hodgkin′s lymphoma to combined treatment with irinotecan HCI and mitoxantrone and the nursing strategy for such patients.Methods Adverse effects including delayed diarrhea,neutropenia,nausea,vomiting and constipation were observed in 12 patients with non-hodgkin＇s lymphoma after combined treatment with irinotecan HCI and mitoxantrone.Results Of the 12 patients,4 had complete remission and 4 partial remission of the disease,with a total effective rate of 66.6%.Four weeks after careful nursing of the 12 patients,the adverse effects were effectively controlled,with no other complications occurred.Conclusion The suffering of patients with non-hodgkin＇s lymphoma can be relieved and the therapeutic effect can be improved by closely observing the toxic reactions of patients to chemotherapy and effectively nursing the patients.